tiprankstipranks
Trending News
More News >
Tsumura & Co. (JP:4540)
:4540

Tsumura & Co (4540) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Tsumura & Co

(OTC:4540)

Rating:69Neutral
Price Target:
¥3,756.00
▲(12.73%Upside)
The overall score of 68.8 reflects strong financial performance and attractive valuation metrics, offset by bearish technical indicators. The stock's low P/E ratio and solid dividend yield are major positives, but current price momentum is a significant risk factor.

Tsumura & Co (4540) vs. iShares MSCI Japan ETF (EWJ)

Tsumura & Co Business Overview & Revenue Model

Company DescriptionTsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyTsumura & Co primarily generates revenue through the sale of its Kampo medicines. The company develops, manufactures, and distributes these herbal products to healthcare professionals, pharmacies, and hospitals. This revenue stream is supported by Tsumura's robust research and development efforts, which ensure the efficacy and safety of their products. Additionally, the company may engage in partnerships with other pharmaceutical companies and research institutions to enhance their product offerings and expand their market reach. Tsumura's focus on quality control and adhering to stringent regulatory standards further solidifies its position in the market, contributing to its revenue generation.

Tsumura & Co Financial Statement Overview

Summary
Tsumura & Co is in a strong financial position with consistent revenue growth, robust profit margins, and improving cash flows. The balance sheet is solid with a conservative debt-to-equity ratio and substantial ROE. While liabilities could pose a risk if not monitored, the overall financial health is robust.
Income Statement
85
Very Positive
Tsumura & Co has demonstrated a strong performance with consistent revenue growth, notably increasing from previous years. The TTM (Trailing-Twelve-Months) data shows a revenue growth rate of approximately 13.9% compared to the previous year. Gross profit margins are robust at 48.7%, and net profit margins are healthy at 15.8%. EBIT and EBITDA margins are also strong at 19.4% and 25.8%, respectively, indicating efficient operations and strong profitability.
Balance Sheet
78
Positive
The balance sheet is solid with a debt-to-equity ratio of 0.28, reflecting a conservative level of leverage. The return on equity (ROE) is substantial at 9.3%, indicating effective use of shareholders' equity to generate profits. The equity ratio stands at 62.9%, showcasing a strong capital structure with a significant portion of assets financed by equity. However, the relatively high level of total liabilities, though manageable, could pose a risk if not carefully monitored.
Cash Flow
80
Positive
Cash flow from operations remains strong, with a significant increase in free cash flow in the TTM period, growing from a negative figure in the previous year to 7.27 billion. The operating cash flow to net income ratio is robust at 1.06, indicating efficient cash generation relative to net income. The free cash flow to net income ratio has improved significantly, reflecting better capital expenditure management.
Breakdown
TTMMar 2024Mar 2023Mar 2022Mar 2021Mar 2020
Income StatementTotal Revenue
171.79B150.84B140.04B129.55B130.88B123.25B
Gross Profit
83.56B68.82B68.28B66.47B74.93B72.50B
EBIT
33.25B20.02B20.92B22.38B19.38B18.88B
EBITDA
44.38B34.82B31.53B31.57B28.00B25.28B
Net Income Common Stockholders
27.12B16.71B16.48B18.84B15.33B13.77B
Balance SheetCash, Cash Equivalents and Short-Term Investments
83.05B78.08B94.75B67.55B61.31B61.96B
Total Assets
463.81B428.25B396.81B350.98B319.06B311.04B
Total Debt
80.36B79.69B79.69B49.69B52.85B65.27B
Net Debt
-132.00M1.61B-15.06B-17.86B-8.46B3.31B
Total Liabilities
145.49B132.89B124.57B92.87B85.89B97.99B
Stockholders Equity
291.89B270.80B252.04B239.77B217.78B205.38B
Cash FlowFree Cash Flow
7.27B-14.45B1.74B10.73B6.69B7.64B
Operating Cash Flow
28.88B5.61B16.45B21.31B16.10B18.19B
Investing Cash Flow
-18.65B-19.35B-15.49B-9.11B-7.35B-23.49B
Financing Cash Flow
-8.54B-4.42B24.42B-8.18B-10.43B7.11B

Tsumura & Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3332.00
Price Trends
50DMA
3951.47
Negative
100DMA
4153.21
Negative
200DMA
4313.42
Negative
Market Momentum
MACD
-191.73
Negative
RSI
20.95
Positive
STOCH
14.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4540, the sentiment is Negative. The current price of 3332 is below the 20-day moving average (MA) of 3476.70, below the 50-day MA of 3951.47, and below the 200-day MA of 4313.42, indicating a bearish trend. The MACD of -191.73 indicates Negative momentum. The RSI at 20.95 is Positive, neither overbought nor oversold. The STOCH value of 14.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4540.

Tsumura & Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$254.92B7.8011.16%3.01%20.05%94.28%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
$2.21B15.1713.50%
$2.24B16.677.90%1.81%
$1.22B15.085.47%2.44%
$1.23B28.254.56%2.13%
73
Outperform
¥78.43B9.42
3.49%8.83%70.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4540
Tsumura & Co
3,332.00
-588.78
-15.02%
DNPUF
Sumitomo Dainippon Pharma Co
5.58
3.32
146.90%
HTSUF
Hisamitsu Pharmaceutical Co
32.30
8.48
35.60%
KSPHF
Kissei Pharmaceutical Co
27.13
6.99
34.71%
TRXPF
Torii Pharmaceutical Co
36.62
13.56
58.80%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,490.00
-144.70
-8.85%

Tsumura & Co Corporate Events

Tsumura & Co. Reports Progress on Share Repurchase Program
May 12, 2025

Tsumura & Co. has announced the intermediate results of its share repurchase program, which was initiated following a board resolution in February 2025. As of April 30, 2025, the company has repurchased 707,300 shares at a total cost of approximately 3.03 billion yen, reflecting its strategic efforts to enhance shareholder value and optimize capital structure.

Tsumura & Co. Unveils Ambitious Growth Plan for 2025-2027
May 12, 2025

Tsumura & Co. has announced its second Medium-Term Management Plan for fiscal years 2025 to 2027, focusing on growth strategies and investments to achieve ‘Cho-WA’ or harmony. The plan includes expanding the Kampo market, entering the traditional Chinese medicinal products business in China, and enhancing digital transformation to improve customer experience. The company aims for stable growth in domestic markets and expansion in China, with a target of JPY234 billion in sales and JPY43 billion in operating profit by 2027.

Tsumura & Co. Revises Stock Compensation System to Align with Long-term Vision
May 12, 2025

Tsumura & Co. announced a revision to its performance-based stock compensation system for directors and executive officers, aligning it with their long-term vision ‘Cho-WA’ 2031. The revision aims to strengthen the link between executive compensation and corporate value, promoting sustainable growth and enhancing corporate value over the medium to long term. The changes, which include increasing the maximum contribution and the number of shares granted, are subject to shareholder approval.

Tsumura & Co. Extends Employee Stock Delivery System to Boost Engagement
May 12, 2025

Tsumura & Co. has announced the continuation of its trust-type stock delivery system for employees, initially introduced in 2023. This system aims to align employee incentives with the company’s long-term visions, including sustainability and management goals, by offering shares or cash equivalents based on performance targets. The initiative is part of the company’s medium-term management plan, running from fiscal years 2025 to 2027, and is designed to enhance employee engagement and contribution to corporate objectives.

Tsumura & Co Reports Strong Financial Growth for FY 2025
May 12, 2025

Tsumura & Co reported a significant increase in its consolidated financial results for the fiscal year ended March 31, 2025, with net sales rising by 20.1% and operating profit doubling compared to the previous year. The company’s strong performance is reflected in its increased dividends and improved financial condition, indicating a robust market position and positive outlook for stakeholders.

Tsumura & Co. Reports Progress on Share Repurchase Program
Apr 7, 2025

Tsumura & Co. announced the intermediate results of its share repurchase program, where it acquired 206,400 shares at a cost of 908,870,200 yen. This move is part of a broader strategy approved by the board to repurchase up to 1,465,000 shares, with a maximum expenditure of 5 billion yen, aimed at enhancing shareholder value and optimizing capital structure.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.